[{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Rabies Immunoglobulin","moa":"antineoplastics (mitotic inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Fernanda P Silveira","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Cytomegalovirus Immunoglobulin","moa":"CMV","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Fernanda P Silveira","highestDevelopmentStatusID":"11","companyTruncated":"Kamada \/ Fernanda P Silveira"},{"orgOrder":0,"company":"Kamada","sponsor":"AcuCort","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Agreement","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Kamada \/ Kamada","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Kamada"},{"orgOrder":0,"company":"Kamada","sponsor":"Kamada","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Alpha 1-Antitrypsin","moa":"Leukocyte elastase","graph1":"Endocrinology","graph2":"Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Kamada","highestDevelopmentStatusID":"8","companyTruncated":"Kamada \/ Kamada"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Alpha 1-Antitrypsin","moa":"Leukocyte elastase","graph1":"Endocrinology","graph2":"Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Alpha-1 Antitrypsin","moa":"ELA2\/HIV-1 protease\/Serine protease||Leukocyte elastase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Kamada \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"ELA2\/HIV-1 protease\/Serine protease||Leukocyte elastase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"ELA2\/HIV-1 protease\/Serine protease||Leukocyte elastase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"ELA2\/HIV-1 protease\/Serine protease||Leukocyte elastase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Alpha-1 Antitrypsin","moa":"ELA2\/HIV-1 protease\/Serine protease||Leukocyte elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Kamada","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Kamada \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Kamada \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Alpha1-proteinase Inhibitor","moa":"Leukocyte elastase","graph1":"Immunology","graph2":"Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Alpha 1-Antitrypsin","moa":"Leukocyte elastase","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Baxalta Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Alpha1-proteinase Inhibitor","moa":"Leukocyte elastase","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Kamada","highestDevelopmentStatusID":"9","companyTruncated":"Kamada \/ Kamada"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Rabies Immune Globulin (Human)","moa":"Rabies Virus Proteins","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Rabies Immune Globulin (Human)","moa":"Rabies Virus Proteins","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"11","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Rabies Immune Globulin (Human)","moa":"Rabies Virus Proteins","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Kamada","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Kamada"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Kamada Anti-SARS-CoV-2","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Cytomegalovirus Immune Globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Cytomegalovirus Immune Globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Saol therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Ganciclovir","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Kamada \/ Kamada","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Kamada"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Human Rabies Immunoglobulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"10","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Human, Alpha-1 Antitrypsin","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Human, Alpha-1 Antitrypsin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Varicella Zoster Immune Globulin (Human)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kamada","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Kamada \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Kamada \/ Syneos Health"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Israeli Health Authorities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Israeli Health Authorities","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Israeli Health Authorities"},{"orgOrder":0,"company":"Kamada","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Kedrion","highestDevelopmentStatusID":"7","companyTruncated":"Kamada \/ Kedrion"},{"orgOrder":0,"company":"Kamada","sponsor":"Camille N. Kotton","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody-protein Conjugate","year":"2025","type":"Inapplicable","leadProduct":"CMV Immune Globulin","moa":"CMV","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Camille N. Kotton","highestDevelopmentStatusID":"11","companyTruncated":"Kamada \/ Camille N. Kotton"},{"orgOrder":0,"company":"Kamada","sponsor":"Impatients N.V. trading as myTomorrows","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Alpha1-Proteinase Inhibitor (Human)","moa":"Leukocyte elastase","graph1":"Immunology","graph2":"Undisclosed","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamada \/ Impatients N.V. trading as myTomorrows","highestDevelopmentStatusID":"1","companyTruncated":"Kamada \/ Impatients N.V. trading as myTomorrows"}]
Find Clinical Drug Pipeline Developments & Deals by Kamada
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
